<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2025-02-20</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972940/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">The Natural Course of Bosch-Boonstra-Schaaf Optic Atrophy Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972940-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    (Likely) pathogenic variants in NR2F1 are associated with Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS, OMIM #615722), a rare neurodevelopmental disorder. Patients present with a variety of symptoms, including intellectual disability, developmental delay, visual impairment, muscular hypotonia, seizures, and/or autistic features. Since it was first described in 2014, the phenotype has steadily expanded. However, there is limited information regarding the natural course of the &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39973088/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Shared Environment - Different Genes: Speech-Language Development in a Pair of Dizygotic Twins with and Without &lt;em&gt;MECP2&lt;/em&gt; Mutation</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39973088-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    This retrospective study compared the speech-language development of a pair of dizygotic twin girls during the first 2 years of life: one with typical development (Twin A) and one with atypical development (Twin B), who was later diagnosed with Rett syndrome (RTT). Audio snippets were extracted from home videos, with nearly equal representation from each child. The audio analysis focused on articulatory complexity, voice characteristics, and linguistic variability. Despite sharing the &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39973726/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Exploring the professional wellbeing of Grade 2 occupational therapists employed in public health inpatient settings in Victoria, Australia: A mixed-methods study</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39973726-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: This research contributes to the growing understanding of professional wellbeing amongst Grade 2 occupational therapists working in hospital environments, and the factors that contribute to and hinder their &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39973942/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39973942-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN patients by reducing FN-related morbidity and mortality and by the continuation of cancer treatment. This guideline describes an evidence-based approach to risk stratification, epidemiology, diagnosis, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39974428/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Correction to: &#39;On Multimatrix Models Motivated by Random Noncommutative Geometry II: A Yang-Mills-Higgs Matrix Model&#39;</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39974428-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    [This corrects the article DOI: 10.1007/s00023-021-01138-w.]. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39975227/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20250220170939&amp;v=2.18.0.post9&#43;e462414">Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39975227-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20250220170939-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Given the successful graft-versus-leukemia cell treatment effect observed with allogeneic hematopoietic stem cell transplant for patients with refractory or relapsed acute myeloid leukemia, immunotherapies have also been investigated in the nontransplant setting. Here, we use a multi-omic approach to investigate spatiotemporal interactions in the bone marrow niche between leukemia cells and immune cells in patients with refractory or relapsed acute myeloid leukemia treated with a combination &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39975540/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Scalable network emulation on analog neuromorphic hardware</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39975540-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We present a novel software feature for the BrainScaleS-2 accelerated neuromorphic platform that facilitates the partitioned emulation of large-scale spiking neural networks. This approach is well suited for deep spiking neural networks and allows for sequential model emulation on undersized neuromorphic resources if the largest recurrent subnetwork and the required neuron fan-in fit on the substrate. We demonstrate the training of two deep spiking neural network models-using the MNIST &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39975711/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Clinical practice guidelines and statements from key professional respiratory societies: the status quo</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39975711-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976199/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Cardiovascular training for fatigue in people with cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976199-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    RATIONALE: Cancer-related fatigue (CRF) is the most prevalent and severe symptom among people with cancer. It can be attributed to the cancer itself or to anticancer therapies. CRF affects the individual physically and mentally, and cannot be alleviated by rest. Studies show a positive effect of exercise on &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976387/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20250220170949&amp;v=2.18.0.post9&#43;e462414">CSGDN: contrastive signed graph diffusion network for predicting crop gene-phenotype associations</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976387-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20250220170949-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Positive and negative association prediction between gene and phenotype helps to illustrate the underlying mechanism of complex traits in organisms. The transcription and regulation activity of specific genes will be adjusted accordingly in different cell types, developmental timepoints, and physiological states. There are the following two problems in obtaining the positive/negative associations between gene and phenotype: (1) high-throughput DNA/RNA sequencing and phenotyping are expensive &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976417/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976417-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976727/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Nontechnical skills in anesthesiology-Introduction</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976727-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Over the last two decades the concepts of &ldquo;human factors&rdquo; and &ldquo;nontechnical skills&rdquo;, which describe the interaction of physical, psychological, cognitive and social characteristics of people with their environment and which have a significant influence on safe patient care, have become established in anesthesiology. Nevertheless, findings from the social sciences and safety research, particularly with respect to understanding human factors and the development and prevention of incidents, have &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976728/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Nontechnical skills in anesthesiology-Implementation</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976728-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In the second of two articles the practical application of nontechnical skills in anesthesiological patient care is presented. Based on the categories of the behavioral marker system anesthesia nontechnical skills (ANTS), the skills situational awareness, decision making, task management, teamwork and communication are discussed. For each category the terminology is clarified and the reasons for support through nontechnical skills and their specific application are given. Tips for everyday &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976935/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Performance of 8 Smoking Metrics for Modeling Survival in Head and Neck Squamous Cell Carcinoma</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976935-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND RELEVANCE: In this cohort study, smoking duration and log cig-years best modeled a linear relationship with OS for patients with HNSCC. Both metrics maintained robust performance within specific clinicodemographic subgroups and anatomic subsites. Although most HNSCC survival models control for smoking exposure using smoking status or pack-years, duration and log cig-years may be superior metrics to account for the effects of smoking on &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976941/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976941-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976942/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976942-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976943/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Oral pathogens exacerbate chronic GVHD</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976943-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976944/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Antibiotics: bad bugs for CAR-T cells?</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976944-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976945/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">New free light chain range decreases LC-MGUS</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976945-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976946/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Deciphering Langerhans cell histiocytosis</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976946-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976947/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">A belt-and-suspenders approach to PNH</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976947-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39976948/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Appreciating the oral microbiome&#39;s impact on GVHD</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39976948-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.npr.org/2025/02/20/1232637594/the-evolution-of-presidential-power">The Evolution of Presidential Power</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-20</span>
  </div>
  <div class="summary">
    <a href="/post/www-npr-org-2025-02-20-1232637594-the-evolution-of-presidential-power/">
    
    
    
    
    
      
    
    What can and can&rsquo;t the president do — and how do we know? The framers of the U.S. Constitution left the powers of the executive branch powers deliberately vague, and in doing so opened the door for every president to decide how much power they could claim. Over time, that&rsquo;s become quite a lot. This episode originally ran in 2020 and has been updated with new material.<!-- raw HTML omitted --><!-- raw HTML omitted -->To access bonus episodes and listen to Throughline sponsor-free, subscribe to Throughline+ via Apple Podcasts or at plus.npr.org/throughline.<!-- raw HTML omitted --><!-- raw HTML omitted -->Learn more about sponsor message choices: &lt;a href=&ldquo;https://podcastcho &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39966902/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Stereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39966902-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In this retrospective analysis, patients who received CIRT presented excellent local tumor control and had better oncologic outcomes than patients who received photon-based SBRT. SBRT with carbon ions is a promising local ablative treatment option that needs further investigation in large prospective &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39967059/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Evaluating interactions of patients with large language models for medical information</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39967059-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    OBJECTIVES: To explore the interaction of real-world patients with a chatbot in a clinical setting, investigating key aspects of medical information provided by large language models &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39967201/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Growth Differentiation Factor-15: A Promising Biomarker and Target in Cancer Patients</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39967201-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39967768/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">General design flow for waveguide Bragg gratings</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39967768-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Bragg gratings are crucial components in passive photonic signal processing, with wide-ranging applications including biosensing, pulse compression, photonic computing, and addressing. However, the design of integrated waveguide Bragg gratings (WBGs) for arbitrary wavelengths presents significant challenges, especially when dealing with highly asymmetric layer stacks and large refractive index contrasts. Convenient approximations used for fiber Bragg gratings generally break down in these &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968049/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Entropy Scaling of Viscosity IV-Application to 124 Industrially Important Fluids</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968049-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In our previous work [Yang X.J. Chem. Eng. Data2021, 66, 1385-1398], a residual entropy scaling (RES) approach was developed to link viscosity to residual entropy using a 4-term power function for 39 refrigerants. In further research [Yang X.Int. J. Thermophys.2022, 43, 183], this RES approach was extended to 124 pure fluids containing fluids from light gases (hydrogen and helium) to dense fluids (e.g., heavy hydrocarbons) and fluids with strong association force (e.g., water). In these &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968356/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20250219171044&amp;v=2.18.0.post9&#43;e462414">Model Architecture Analysis and Implementation of TENET for Cell-Cell Interaction Network Reconstruction Using Spatial Transcriptomics Data</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968356-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20250219171044-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cellular communication relies on the intricate interplay of signaling molecules, which come together to form the cell-cell interaction (CCI) network that orchestrates tissue behavior. Researchers have shown that shallow neural networks can effectively reconstruct the CCI from the abundant molecular data captured in spatial transcriptomics (ST). However, in scenarios characterized by sparse connections and excessive noise within the CCI, shallow networks are often susceptible to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968356/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20250220170949&amp;v=2.18.0.post9&#43;e462414">Model Architecture Analysis and Implementation of TENET for Cell-Cell Interaction Network Reconstruction Using Spatial Transcriptomics Data</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968356-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20250220170949-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cellular communication relies on the intricate interplay of signaling molecules, which come together to form the cell-cell interaction (CCI) network that orchestrates tissue behavior. Researchers have shown that shallow neural networks can effectively reconstruct the CCI from the abundant molecular data captured in spatial transcriptomics (ST). However, in scenarios characterized by sparse connections and excessive noise within the CCI, shallow networks are often susceptible to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968388/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Head-to-head comparisons of risk discrimination by questionnaire-based lung cancer risk prediction models: a systematic review and meta-analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968388-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: While different lung cancer risk prediction models have been established as essential tools to identify high-risk participants for lung cancer screening programs, evaluations of their risk discriminatory performances have reported heterogenous findings in different research cohorts. We therefore aimed to summarise results of head-to-head comparisons of the predictive performance of various lung cancer risk models performed within the same study &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968416/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20250219171044&amp;v=2.18.0.post9&#43;e462414">MONet: cancer driver gene identification algorithm based on integrated analysis of multi-omics data and network models</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968416-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20250219171044-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cancer progression is orchestrated by the accrual of mutations in driver genes, which endow malignant cells with a selective proliferative advantage. Identifying cancer driver genes is crucial for elucidating the molecular mechanisms of cancer, advancing targeted therapies, and uncovering novel biomarkers. Based on integrated analysis of Multi-Omics data and Network models, we present MONet, a novel cancer driver gene identification algorithm. Our method utilizes two graph neural &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968416/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20250220170949&amp;v=2.18.0.post9&#43;e462414">MONet: cancer driver gene identification algorithm based on integrated analysis of multi-omics data and network models</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968416-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20250220170949-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cancer progression is orchestrated by the accrual of mutations in driver genes, which endow malignant cells with a selective proliferative advantage. Identifying cancer driver genes is crucial for elucidating the molecular mechanisms of cancer, advancing targeted therapies, and uncovering novel biomarkers. Based on integrated analysis of Multi-Omics data and Network models, we present MONet, a novel cancer driver gene identification algorithm. Our method utilizes two graph neural &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968597/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Review of the foundations of time-dependent density-functional theory (TDDFT)</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968597-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Time-dependent density-functional theory (TDDFT) is deemed to be a formally rigorous way of dealing with the time-evolution of a many-electron system at the level of electron densities rather than the underlying wavefunctions, which in turn provides an, in principle, exact density-based approach to the treatment of electron excitations in atoms and molecules. This claim has not remained unchallenged, and a detailed account of the relevant criticism is given in this paper. In view of our &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39968763/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Google infodemiology and temporal trends in benign prostatic hyperplasia surgery in Australia</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39968763-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Differences were found between GT analysis and actual BPH procedures performed at a population level. This study highlights that clinicians need to adapt and provide better patient counselling to ensure a shared decision-making process when choosing the treatment procedure for BPH/male &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39969525/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20250219171040&amp;v=2.18.0.post9&#43;e462414">Native stem cell transcriptional circuits define cardinal features of high-risk leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39969525-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20250219171040-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors remains elusive. Using complementary mouse and human models, chromatin mapping, and enhancer profiling, we show that the coactivator ZMIZ1 promotes normal and malignant ETP population growth by inducing the transcription factor MYB in feedforward circuits to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39969525/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20250220170944&amp;v=2.18.0.post9&#43;e462414">Native stem cell transcriptional circuits define cardinal features of high-risk leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39969525-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20250220170944-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors remains elusive. Using complementary mouse and human models, chromatin mapping, and enhancer profiling, we show that the coactivator ZMIZ1 promotes normal and malignant ETP population growth by inducing the transcription factor MYB in feedforward circuits to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39969538/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39969538-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39969590/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Advantages in orthopaedic implant infection diagnostics by additional analysis of explants</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39969590-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: This study showed with a higher frequency of bacterial detection of orthopedic explant´s surface compared to tissue samples or punction fluid. This may reduce the number of samples and cost but enhances the quality of orthopaedic implant-related infection &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39969732/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250219171046&amp;v=2.18.0.post9&#43;e462414">Glutaric aciduria type 1 - a rare treatable neurometabolic disorder of lysine metabolism</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39969732-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250219171046-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Glutaric aciduria type 1 (OMIM #231670) is a rare inherited neurometabolic disorder of lysine and tryptophan metabolism. The deficiency of mitochondrial glutaryl-CoA dehydrogenase activity leads to an accumulation of neurotoxic metabolites such as glutaric acid and 3-hydroxyglutaric acid in the body. Most untreated patients develop a dystonic movement disorder due to striatal injury during the first years of life associated with increased morbidity and mortality. However, early diagnosis &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970324/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970324-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment clinical trials have indicated that in eligible patients, allo-HCT is associated with superior clinical outcomes compared to non-transplant therapy. However, this therapeutic option is only &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970325/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">Immunoactinopathies revisited: Understanding clinical manifestations and biological pathways</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970325-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Immune cell functionality is highly dependent on the actin cytoskeleton. The actin cytoskeleton is regulated by a complex molecular machinery, involving multiple genes. Mutations in these genes can cause inborn errors of immunity, also termed immunoactinopathies, of which Wiskott Aldrich Syndrome is the best-characterized entity. At present, mutations in 23 genes can be considered causative of immunoactinopathies. Immunoactinopathies are rare disease entities with complex combinations &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970326/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20250220170938&amp;v=2.18.0.post9&#43;e462414">How I treat patients who are refractory to platelet transfusions</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970326-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20250220170938-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Patients with thrombocytopenia requiring on-going platelet transfusion support may develop inadequate platelet count increments, referred to as Platelet Refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and non-immune causes. A high index of suspicion is required to initiate testing for alloimmunization and t leading culprit in immune PR is development of Class I Human Leukocyte Antigens (HLA) antibodies. The approach &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970402/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">A Hitchhiker&#39;s Guide to Antibody-Mediated Rejection</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970402-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970403/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Another Win for SGLT2 Inhibitors in Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970403-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970404/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">The Duration of Immunotherapy for Mismatch Repair-Deficient Cancers</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970404-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970405/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970405-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970406/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970406-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970407/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease. Reply</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970407-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970408/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Biomarkers and 30-Year Cardiovascular Outcomes in Women</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970408-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970409/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Biomarkers and 30-Year Cardiovascular Outcomes in Women</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970409-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970410/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Biomarkers and 30-Year Cardiovascular Outcomes in Women. Reply</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970410-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970411/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970411-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970412/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970412-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970413/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970413-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970414/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970414-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39970420/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20250220170943&amp;v=2.18.0.post9&#43;e462414">Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39970420-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20250220170943-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39971965/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39971965-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between survival endpoints and common germline variants in 753 endocrine resistance-related genes. For a discovery cohort, we screened the Breast Cancer Association Consortium database (n ≥ 90,000 cases) and retrieved 2789 AI-treated patients. Cox model-based analysis revealed 125 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972009/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Roadmap for alleviating the manifestations of ageing in the cardiovascular system</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972009-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Ageing of the cardiovascular system is associated with frailty and various life-threatening diseases. As global populations grow older, age-related conditions increasingly determine healthspan and lifespan. The circulatory system not only supplies nutrients and oxygen to all tissues of the human body and removes by-products but also builds the largest interorgan communication network, thereby serving as a gatekeeper for healthy ageing. Therefore, elucidating organ-specific and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972038/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972038-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chronic Kidney Disease (CKD) is associated with heightened risk of thrombosis. Prescription of anticoagulants is key to manage it; however, CKD patients have shown an increased risk of bleeding under anticoagulation therapy compared to non-CKD patients. We hypothesized that the sex could modify the metabolism of indoxyl sulfate (IS), a uremic toxin and Apixaban. Our intoxication model shows that higher doses of IS and apixaban accumulate in the plasma of female mice because of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972134/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Clonal driver neoantigen loss under EGFR TKI and immune selection pressures</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972134-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (EGFR)-driven lung cancers^(1,2). We tracked the phylogenetic history of an EGFR mutant lung cancer treated with erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine (NPV) targeting ten somatic mutations, including EGFR exon 19 deletion (ex19del). The ex19del mutation was clonal, but is likely to have appeared after a whole-genome doubling (WGD) event. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a resection with 5-year overall survival (OS) rates of up to 25%. In the Netherlands, the nationwide resection rate for LAPC remains low at 8%. The PREOPANC-4 program aims for a nationwide implementation of the international multidisciplinary best-practice &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972292/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Interpersonal vs. supportive group psychotherapy for depression attributed to work stress: study protocol of the multicentre, cluster-randomised, controlled IPT-Work trial</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972292-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Depression associated with occupational stress is highly prevalent, causing high rates of sick leave and thus posing significant societal and economic burden. Meta-analyses of the few studies on psychological and work-focused interventions for common mental disorders including depression report small effects on depressive symptomatology and occupational outcomes. There is an urgent need for more controlled studies on work-directed interventions assessing work &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972337/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Envisioning sustainable oral health through effective advocacy</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972337-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In recent years, global commitments have endeavored to reduce the burden of oral diseases. To maintain this momentum, effective advocacy for sustainable oral health is needed to raise public awareness, garner support, and guide policy makers. However, there has been limited use of evidence-based frameworks and approaches to design and measure the impact of oral health advocacy efforts. The 2nd Global Oral Health Forum (GOHF II) was hosted in April 2024 over a 2-day period to reflect on &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972395/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">No disadvantages for women in acute stroke care in Germany: an analysis of access to stroke treatment services in Germany from 2017 to 2022</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972395-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: We found no evidence that female stroke patients in Germany face any disadvantage in accessing stroke treatment services. Acute stroke treatment rates were generally similar or higher when compared to males. Higher intrahospital mortality and lower SU rates were attributed to greater age, comorbidities, and stroke severity. However, the differences were not fully explained when adjusting for AF and age. Further research is needed on sex differences in stroke mechanisms and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39972401/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20250220170953&amp;v=2.18.0.post9&#43;e462414">Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases</a></h1>
  <div class="date-author">
    
    <span class="date">2025-02-19</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39972401-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250220170953-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) have increasingly been reported to impact the brain metastatic process of solid tumors. However, data on intra-individual differences between primary tumor and brain metastasis (BM), as well as their correlation with clinical outcome parameters, is &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

